Shopping Cart
- Remove All
Your shopping cart is currently empty
Sonrotoclax TFA
Catalog No. T74637L
Alias Sonrotoclax TFA(2383086-06-2 Free base), BGB 11417 TFA
Sonrotoclax TFA is an orally available and highly potent and selective Bcl-2 inhibitor of WT and G101V mutants with antitumor activity for the study of hematologic malignancies.
Sonrotoclax TFA
Catalog No. T74637LAlias Sonrotoclax TFA(2383086-06-2 Free base), BGB 11417 TFA
Sonrotoclax TFA is an orally available and highly potent and selective Bcl-2 inhibitor of WT and G101V mutants with antitumor activity for the study of hematologic malignancies.
Product information is being updated, if you want to purchase, please click the bulk custom button.
Bulk & Custom
Questions
View MoreInhibitors Related to "Sonrotoclax TFA"
Navitoclax
Cited
ABT-263
T2101923564-51-6
Navitoclax (ABT-263) is a potent oral Bcl-2 inhibitor that binds to Bcl-xL, Bcl-2, and Bcl-w proteins (Ki<1 nM), demonstrating antitumor activity and inducing apoptosis.
- $41
Size
QTY
CitedVenetoclax Cited
GDC-0199, ABT-199, ABT199, ABT 199
T21191257044-40-8
Venetoclax (ABT-199) is a Bcl-2 inhibitor (Ki<0.01 nM) with potent, selective, and orally active properties. Venetoclax has a 3-order-of-magnitude lower affinity for Bcl-xL and Bcl-W (Kis=48/245 nM). Venetoclax induces autophagy and apoptosis.
- $48
Size
QTY
Cited(S)-(+)-Ibuprofen
Dexibuprofen, (S)-Ibuprofen
T044851146-56-6
(S)-(+)-Ibuprofen (Dexibuprofen) , is a non-steroidal anti-inflammatory drug (NSAID), inhibiting cyclooxygenase (COX).
- $35
Size
QTY
Lisaftoclax
Bcl-2/Bcl-xl inhibitor 1, APG-2575
T104832180923-05-9
Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells.
- $187
Size
QTY
Gossypol
Pogosin, NSC 56817, BL 193
T6518303-45-7
Gossypol (BL 193) Acetate is a polyphenolic aldehyde that permeates cells and acts as an inhibitor for several dehydrogenase enzymes.
- $35
Size
QTY
Triacetylresveratrol
Acetyl-trans-resveratrol
T566842206-94-0
Triacetylresveratrol (Acetyl-trans-resveratrol) has anti-cancer activity,it inhibits the phosphorylation of STAT3 and NFκB, down-regulates Mcl-1, and up-regulates Bim and Puma in pancreatic cancer cells.
- $68
Size
QTY
Diphenyl disulfide
Phenyl disulfide
T37518882-33-7
Diphenyl disulfide (Phenyl disulfide) shows anticancer activity in breast cancer cell lines.Diphenyl disulfide induces and enhances apoptosis in breast cancer cells through Bax protein hydrolysis activation and concomitant autophagy.Diphenyl disulfide inhibits cell proliferation and viability and reduces colony formation in a dose-dependent manner. Diphenyl disulfide can be used to treat breast cancer.
- $30
Size
QTY
Gossypol (acetic acid) Cited
Pogosin, Gossypol acetic acid, AT101, (±)-Gossypol-acetic acid
T273012542-36-8
Gossypol acetic acid (AT101), a polyphenolic compound isolated from cottonseeds, binds with Bcl-2, Bcl-xL, Mcl-1, and does not inhibit BIR3 domain and BID.
- $30
Size
QTY
Cited(E)-Ferulic acid
trans-Ferulic acid, (E)-Coniferic acid
T5679537-98-4
(E)-Ferulic acid ((E)-Coniferic acid) causes the phosphorylation of β-catenin, resulting in proteasomal degradation of β-catenin and increases the expression of pro-apoptotic factor Bax and decreases the expression of pro-survival factor survivin.t(E)-Ferulic acid exert both anti-proliferation and anti-migration effects in the human lung cancer cell line H1299.
- $34
Size
QTY
Docetaxel trihydrate
RP-56976 (Trihydrate), RP56976 (NSC 628503) Trihydrate
T0186148408-66-6
Docetaxel trihydrate (RP-56976 Trihydrate) is an antineoplastic agent that has a unique mechanism of action as an inhibitor of cellular mitosis and that currently plays a central role in the therapy of many solid tumor including breast and lung cancer. Therapy with docetaxel has been associated with a low rate of serum enzyme elevations and rarely to instances of acute hepatic necrosis generally due to severe hypersensitivity reactions or sepsis.
- $46
Size
QTY
Rasagiline
TVP1012, AGN1135
T1119136236-51-6
Rasagiline (AGN1135) is an inhibitor of monamine oxidase used as adjunctive therapy in combination with levodopa and carbidopa in the management of Parkinsons disease.
- $34
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Sonrotoclax TFA is an orally available and highly potent and selective Bcl-2 inhibitor of WT and G101V mutants with antitumor activity for the study of hematologic malignancies. |
| In vivo | A once-daily oral dose of 5-50 mg/kg Sonrotoclax TFA for 42 days exhibited antitumor activity and effectively inhibited tumor growth in a female NCG mouse model suffering from acute lymphoblastic leukemia (ALL) xenografts. [1] |
| Alias | Sonrotoclax TFA(2383086-06-2 Free base), BGB 11417 TFA |
| Molecular Weight | 1004.12 |
| Formula | C51H60F3N7O9S |
Storage & Solubility Information
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Sonrotoclax TFA | purchase Sonrotoclax TFA | Sonrotoclax TFA cost | order Sonrotoclax TFA | Sonrotoclax TFA chemical structure | Sonrotoclax TFA in vivo | Sonrotoclax TFA formula | Sonrotoclax TFA molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.